Nextcea, Inc. 500 West Cummings Park, #4550, Woburn, MA 01801
Tel: 1.800.225.1645 | 781.457.4010


English      About Nextcea Nextcea社について      Home ホーム      Contact Us 問い合わせ          

Drug-Induced Phospholipidosis Services

Drug-Induced Phospholipidosis Services
Drug induced phospholipidosis (DIPL) is a phospholipid storage disorder characterized by an excessive accumulation of multi-lamellar bodies (myeloid bodies) in cells and tissues. Currently more than 350 drug candidates and marketed drugs have been reported to cause DIPL[1]. DIPL has been considered an adverse finding from a regulatory perspective whether justified or not[2]. Since DIPL may be linked to unwanted toxicities, it is important for pharmaceutical researchers and physicians to better understand, track, and manage this drug side effect.
  • Di-docosahexaenoyl (22:6)-BMP
    Bis(mono)acylglycerol phosphate (BMP) is a lysosomal phospholipid that is increased in the tissues of animals and humans with DIPL and NPC disease. A specific species of BMP, di-docosahexaenoyl (22:6)-BMP (di-22:6-BMP), is a biomarker of DIPL in humans and animals that can be monitored in the plasma/serum, urine and tissues[3-6].
  • In vitro Drug-Induced Phospholipidosis Screening
    The in vitro analysis of di-22:6-BMP provides a sensitive and specific high throughput screening assay to rapidly identify compounds with the potential to induce DIPL early in the drug discovery process.
  • Nonclinical & Clinical Studies
    Nextcea uses validated high sensitivity LC-MS/MS methods to measure the concentrations of di-22:6-BMP in biological samples from nonclinical and clinical studies.
    ◄ Case Study: Amiodarone and Chloroquine
    Levels of di-22:6-BMP in the urine of rats treated with 150 mg/kg/day of amiodarone and 120 mg/kg/day of chloroquine (Liu et al. Toxicology and Applied Pharmacology 2014; 279:467-476) Download the abstract
  1. Willard J. FDA phospholipidosis working group preliminary results and developing opinions. Presented at the Society of Toxicology Pathology (STP) Continuing Education Course on Drug-Induced Phospholipidosis June 2008.
  2. Reasor M.J., Hastings K.L., and Ulrich, R.G., Drug-induced phospholipidosis: issues and future directions. Expert Opinion in Drug Safety 2006;5(4), 567-583
  3. Liu N., Tengstrand E., Chourb L., and Hsieh F. Di-22:6-bis(monoacylglycerol)phosphate: A clinical biomarker of drug-induced phospholipidosis for drug development and safety assessment. Toxicology and Applied Pharmacology 2014;279(3):467-476.
  4. Hsieh F., Tengstrand E. Detecting Phospholipidosis and Diagnosing Lysosomal Storage Disorders. US Patent 8,313,949 and Japanese patent (granted).
  5. Tengstrand E., Miwa G., and Hsieh F. Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug induced toxicities. Expert Opinion in Drug Metabolism and Toxicology. 2010 6(5):555-570.
  6. Tengstrand-Baronas E., Lee J.W., Alden C., and Hsieh F. Biomarkers to monitor drug-induced phospholipidosis. Toxicology and Applied Pharmacology 2007;218:72-78.